HC Wainwright Increases Earnings Estimates for Scholar Rock

Scholar Rock Holding Co. (NASDAQ:SRRK) – Equities research analysts at HC Wainwright increased their Q2 2025 earnings per share estimates for Scholar Rock in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.69) per share for the quarter, up from their prior estimate of ($0.72). The consensus estimate for Scholar Rock’s current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock’s Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.73) EPS, FY2026 earnings at ($1.96) EPS, FY2027 earnings at ($1.15) EPS and FY2028 earnings at ($0.12) EPS.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period in the previous year, the business earned ($0.59) earnings per share.

Separately, Wedbush reissued an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, May 14th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $42.67.

Scholar Rock Stock Down 1.3%

Shares of SRRK opened at $30.16 on Monday. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock has a 12 month low of $6.76 and a 12 month high of $46.98. The stock’s 50 day moving average is $31.07 and its two-hundred day moving average is $35.98. The firm has a market cap of $2.86 billion, a P/E ratio of -12.83 and a beta of 0.37.

Insider Activity

In other news, Director Katie Peng sold 1,006 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the transaction, the director now owns 30,319 shares in the company, valued at $1,043,579.98. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the transaction, the insider now owns 111,084 shares in the company, valued at approximately $4,154,541.60. This trade represents a 38.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 223,308 shares of company stock worth $8,044,512 over the last quarter. 13.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Scholar Rock

A number of institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in shares of Scholar Rock by 1.0% in the third quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock valued at $310,000 after buying an additional 379 shares in the last quarter. GF Fund Management CO. LTD. grew its stake in shares of Scholar Rock by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 2,396 shares of the company’s stock valued at $77,000 after buying an additional 430 shares in the last quarter. CWM LLC grew its stake in shares of Scholar Rock by 152.8% in the first quarter. CWM LLC now owns 996 shares of the company’s stock valued at $32,000 after buying an additional 602 shares in the last quarter. Amalgamated Bank grew its stake in shares of Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company’s stock valued at $114,000 after buying an additional 620 shares in the last quarter. Finally, Global Retirement Partners LLC grew its stake in Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after purchasing an additional 766 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.